Your browser doesn't support javascript.
loading
Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update.
Winograd, Joshua; Venishetty, Nikit; Codelia-Anjum, Alia; Bhojani, Naeem; Elterman, Dean; Zorn, Kevin C; Te, Alexis; Chughtai, Bilal.
Afiliación
  • Winograd J; Department of Urology, Weill Cornell Medicine, New York, NY, USA.
  • Venishetty N; Paul L. Foster School of Medicine, Texas Tech Health Sciences Center, El Paso, TX, USA.
  • Codelia-Anjum A; Department of Urology, Weill Cornell Medicine, New York, NY, USA.
  • Bhojani N; Division of Urology, University of Montreal, Montreal, Québec, Canada.
  • Elterman D; Division of Urology, University of Toronto, Toronto, Ontario, Canada.
  • Zorn KC; Division of Urology, University of Montreal, Montreal, Québec, Canada.
  • Te A; Department of Urology, Weill Cornell Medicine, New York, NY, USA.
  • Chughtai B; Department of Urology, Weill Cornell Medicine, New York, NY, USA.
Expert Opin Emerg Drugs ; 29(3): 205-217, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38841744
ABSTRACT

INTRODUCTION:

Benign prostatic hyperplasia (BPH) is a condition that affects over 50% of men as they enter their fifth decade of life, often leading to lower urinary tract symptoms (LUTS). Primary treatment options include alpha blockers, 5-alpha reductase inhibitors, and phosphodiesterase-5 inhibitors. However, these medications can have some side effects, and there is a noticeable dearth of information addressing the long-term use of these medications. Thus, the exploration of all treatment modalities helps ensure patients receive personalized and effective care. Consequently, the primary objective of this review is to identify potential emerging medications for the treatment of BPH. AREAS COVERED We conducted an extensive review of articles discussing pharmacotherapy for BPH spanning the last 15 years. Our information gathering process involved Scopus, PubMed-MEDLINE, Cochrane, Wiley Online Library Google Scholar, ClinicalTrials.gov, and the PharmaProjects database. This approach ensures that readers gain an in-depth knowledge of the existing therapeutic agents as well as promising avenues for managing BPH. EXPERT OPINION BPH treatment targets a patient's specific constellation of symptoms. Therefore, a broad knowledge base encompassing various treatment options is paramount in ensuring optimal treatment. Looking forward, the emphasis on personalization promises to reshape the landscape of BPH treatment and improve patient outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Inhibidores de 5-alfa-Reductasa / Síntomas del Sistema Urinario Inferior / Desarrollo de Medicamentos Límite: Animals / Humans / Male / Middle aged Idioma: En Revista: Expert Opin Emerg Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Inhibidores de 5-alfa-Reductasa / Síntomas del Sistema Urinario Inferior / Desarrollo de Medicamentos Límite: Animals / Humans / Male / Middle aged Idioma: En Revista: Expert Opin Emerg Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido